Finance

Lists
Q2 2026 earnings • released • EPS miss -27.59% • Revenue miss -84.14%
See results
BCYC:NASDAQ
Bicycle Therapeutics PLC
$3.86
-3.74%
(-0.15) 1D
$3.77
-2.38% (-0.092)
After hours
Closed: Jul 31, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BCYC...
Open
$4.01
High
$4.01
Low
$3.80
Mkt. cap
269.47M
Avg. vol.
417.81K
Volume
336.08K
52-wk high
$9.16
52-wk low
$3.80
EPS
-$3.16
Beta
1.55
Shares outstanding
50.37M
No. of employees
288
Open
$4.01
High
$4.01
Low
$3.80
Mkt. cap
269.47M
Avg. vol.
417.81K
Volume
336.08K
52-wk high
$9.16
52-wk low
$3.80
EPS
-$3.16
Beta
1.55
Shares outstanding
50.37M
No. of employees
288
News stories
From sources across the web
About Bicycle Therapeutics PLC
CEOKevin Lee
Employees288
Founded2009
Headquarters-
SectorBiotechnology
Websitebicycletherapeutics.com
Analyst ratings
Based on 6 analysts giving stock ratings to BCYC in the past 3 months
Buy
Buy
3
Hold
3
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for BCYC in the last 3 months.
Highest
Current $3.86
$14.00 (+262.69%)
Average
$9.80 (+153.89%)
Lowest
$5.00 (+29.53%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jeff Jones
Oppenheimer
Buy
Maintained
$11.00
+185%
07/31/2026
Gregory Renza
Truist Financial
Hold
Maintained
$7.00
+81.3%
07/31/2026
Tara Bancroft
TD Cowen
Buy
Maintained
-
-
07/30/2026
Ami Fadia
Needham
Buy
Maintained
$14.00
+262.7%
07/30/2026
Leonid Timashev
RBC Capital
Hold
Maintained
$5.00
+29.5%
07/30/2026
Maxwell Skor
Morgan Stanley
Hold
Maintained
$12.00
+210.9%
05/18/2026
Maury Raycroft
Jefferies
Buy
Maintained
$12.00
+210.9%
04/30/2026
Jay Olson
Oppenheimer
Buy
Maintained
$36.00
+832.6%
03/18/2026
Reni Benjamin
Citizens JMP
Buy
Maintained
$8.00
+107.3%
03/18/2026
Last report
Jul 30, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.72 / -$0.56
-27.59%miss
Revenue / Est. (USD)
629.00K / 3.97M
-84.14%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
11.73M
47.96M
887.00K
629.00K
Cost of goods sold
56.61M
45.92M
46.96M
-
Cost of revenue
56.61M
45.92M
46.96M
-
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
20.67M
22.55M
19.41M
-
Operating expense
20.67M
22.55M
19.41M
-
Total operating expenses
77.28M
68.46M
66.37M
-
Operating income
-65.55M
-20.51M
-65.48M
-
Other non operating income
-
-
-
-
EBT including unusual items
-58.90M
-18.89M
-60.65M
-
EBT excluding unusual items
-58.90M
-14.69M
-60.65M
-
Income tax expense
205.00K
1.26M
172.00K
-
Effective tax rate
-0.35%
-6.70%
-0.28%
-
Other operating expenses
-
-
-
-
Net income
-59.10M
-20.15M
-60.82M
-
Net profit margin
-503.66%
-42.03%
-6,857.38%
-8,002.07%
Earnings per share
-0.85
-0.29
-0.87
-0.72
Interest and investment income
6.70M
5.88M
4.88M
-
Interest expense
-44.00K
-57.00K
-48.00K
-
Net interest expenses
6.66M
5.82M
4.83M
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-63.80M
-19.17M
-64.35M
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps